Drug Trial Radar · NCT04980248
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Sep 28, 2021
Primary completion
Aug 24, 2022
Study completion Aug 24, 2022
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.
Conditions
- Hypophosphatasia
Interventions
ALXN1850Biological
ALXN1850 will be administered as an IV infusion and via the SC route.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 up to Day 85
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Las Vegas, Nevada
Research Site
Columbus, Ohio
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.